GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3030)

  • GC81542 structure
    GC815427-O-Galloyl-D-sedoheptulose
    CAS: 233690-85-2
    Purity: >98%

    7-O-Galloyl-D-sedoheptulose is an orally effective polyphenolic compound.

  • GC81544 structure
    GC81544Copper ionophore I
    CAS: 101264-90-8
    Purity: >98.00%

    Copper ionophore I is an efficient copper ion carrier.

  • GC81546 structure
    GC81546iMQT_020
    CAS: 2463893-46-9
    Purity: >99.00%

    iMQT_020 is a selective allosteric SLC1A5_var inhibitor.

  • GC81547 structure
    GC81547Geranyl isovalerate
    CAS: 109-20-6
    Purity: >96.50%

    Geranyl isovalerate is a chemical component that can be extracted from Argyreia Nervosa.

  • GC81548 structure
    GC81548CIGB-552 TFA
    Purity: >98.00%

    CIGB-552 TFA is a cell-penetrating peptide with anti-tumor properties with the IC 50 of 23 μM in H460 cells.

  • GC81549 structure
    GC8154914-3-3-IN-2
    CAS: 919751-10-3
    Purity: >98.00%

    14-3-3-IN-2 is a 14-3-3 protein inhibitor with an IC 50 of 15 nM.

  • GC81551 structure
    GC81551ZNF281-IN-1
    Purity: >98%

    ZNF281-IN-1 is a ZNF281 inhibitor.

  • GC81556 structure
    GC81556FZ1 peptide
    Purity: >99.50%

    FZ1 peptide is a cyclic heptapeptide and also an integrin αvβ3 agonist.

  • GC81558 structure
    GC81558ANT308 TFA
    Purity: >99.50%

    ANT308 TFA is a vasoactive intestinal polypeptide ( VIP receptor ) antagonist.

  • GC81559 structure
    GC81559Maxadilan TFA
    Purity: >96.00%

    Maxadilan TFA is a specific irreversible PAC1 receptor agonist and a potent vasodilator peptide present in the salivary glands of sand flies.

  • GC81568 structure
    GC81568M464
    Purity: >99.50%

    M464, a non-steroidal anti-inflammatory compound, is a potent and orally active NLRP3 inflammasome inhibitor.

  • GC81574 structure
    GC81574Hydroxyproline
    CAS: 6912-67-0
    Purity: >98.00%

    Hydroxyproline (DL-Hydroxyproline) is a non-essential amino acid and one of the main components of collagenous tissues.

  • GC81594 structure
    GC81594TLSC702
    CAS: 748786-57-4
    Purity: >95.50%

    TLSC702 is a human glyoxalase I ( hGLO I ) inhibitor with an IC 50 of 2.0 μM.

  • GC81595 structure
    GC81595BCS12
    CAS: 329719-71-3
    Purity: >99.50%

    BCS12 is a CAIX inhibitor.

  • GC81596 structure
    GC81596SHMT2-IN-1
    Purity: >99.50%

    SHMT2-IN-1 is a potent serine hydroxymethyltransferase 2 ( SHMT2 ) inhibitor with an IC 50 of 1.21 μM and a K D of 10.6 μM.

  • GC81597 structure
    GC81597Momilactone B
    CAS: 51415-08-8
    Purity: >99.00%

    Momilactone B is an inhibitor of α-amylase and α-glucosidase, with an IC 50 of 146.85 μg/mL against Aspergillus oryzae α-amylase and an IC 50 of 612.03 μg/mL against Saccharomyces cerevisiae α-glucosidase.

  • GC81601 structure
    GC816012-Hydroxymelatonin
    CAS: 229018-17-1
    Purity: >98.00%

    2-Hydroxymelatonin is a major hydroxylated metabolite of Melatonin.

  • GC81605 structure
    GC81605PGK1-IN-1
    CAS: 3093312-81-0
    Purity: >99.50%

    PGK1-IN-1 (Compound 6e) is a potent and selective PGK1 inhibitor ( IC 50 : 33 nM).

  • GC81611 structure
    GC81611Nrf2-IN-4 hydrobromide
    Purity: >99.00%

    Nrf2-IN-4 (Compound PhcY) hydrobromide is a Nrf2 inhibitor.

  • GC81616 structure
    GC81616Flumethrin-d 5
    Purity: >98%

    Flumethrin -d 5 (FCR 2769-d 5 ) is the deuterium labeled Flumethrin.

  • GC81618 structure
    GC81618Urolithin A- 13 C 6
    Purity: >99.50%

    Urolithin A - 13 C 6 is the 13 C-labeled Urolithin A.

  • GC81661 structure
    GC81661Anti-Mouse PD-1 Antibody (RMP1-14), CY7 labeled
    Purity: >98.00%

    Anti-Mouse PD-1 Antibody (RMP1-14), CY7 labeled, is an Anti-Mouse PD-1 Antibody (RMP1-14) derivative carrying dye CY7.

  • GC81673 structure
    GC81673UE01
    CAS: 486440-74-8
    Purity: >98%

    UE01 is an orally active, selective small-molecule modulator targeting both ULK1/ERK1/2.

  • GC81674 structure
    GC81674MKI-3
    CAS: 3084702-28-0
    Purity: >98%

    MKI-3 is a selective microtubule-associated serine/threonine kinase-like ( MASTL ) inhibitor with an IC 50 of 5.72 nM and a K d of 1.89 nM.